Ever wish that really big hill you always cycle up would seem a little less hilly? Want to swing impressive poundage at your next kettlebell class?According to Doug Kalman PhD, RD, Director of Nutrition & Endocrinology at QPS MRA (Miami Research Associates) and other contributors to the International Society of Sports Nutrition’s position paper on …
QPS Aids Development of Cannabinoid Chewing Gum, for MS Patients
Cannabinoid bioscience has come a long way. New York-based Axim Biotech is at the forefront, developing – among many other, related products – a multi-layered, slow-release cannabinoid chewing gum. Not for the candy stand, MedChewRx® is seeking FDA and EMA approval for the treatment of pain and spasticity associated with multiple sclerosis. Characteristically, QPS is …
Mental Vacation
Need a vacation? Don’t have time? Spend the next 45 seconds pretending you’re here.
Sports Nutrition Leadership, Benchtop to Countertop: Watch the Webinar on Building Better Beverages with panelist Doug Kalman, Director of Nutrition & Endocrinology at QPS MRA
Finding something tasty to drink at the mini-mart has gotten really complicated lately. Knowing the usual soft drinks are unhealthy, you may be tempted by the “sport” drink section. But even if you’ve grabbed the colorless option to avoid massive quantities of Blue #1 or Yellow #5, a quick label-read may have you flipping that …
Fast Track Routes for Medicines that address Unmet Medical Needs
Launch of two-month public consultations on revised guidelines on accelerated assessment and conditional marketing authorization The European Medicines Agency (EMA) has revised its guidelines on the implementation of accelerated assessment and conditional marketing authorization, two key tools in the European legislation to accelerate patients’ access to medicines that address unmet medical needs. Accelerated assessment and …
DMPK scientists from Exelixis and QPS publish on “Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites” in DMD
Read the original Exelexis-supported publication in Drug Metabolism & Disposition (DMD). Cabozantinib (COMETRIQ®) inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. Cabozantinib is currently approved …
Dr. Diane Krieger from QPS MRA acknowledged in NEJM for her role as investigator in the SCALE Obesity and Prediabetes Study Group
The sheer abundance of diet drugs available suggests two things: 1) there is a huge market for them and 2) none of them work significantly better than the rest (if at all.) Imagine the excitement, then, at finding that an agent already prescribed for diabetes really can help patients lose significant amounts of weight. And …
Hop on the QPS Bioanalysis Bus: Protein Quantitation by LC-MS/MS is Just Around the Corner
We love it when you notice! At the recent Sciex Users gathering of MS geeks in the 63th ASMS Annual Conference, one member of Team QPS reported: I had total strangers walking up to me to say QPS is the only CRO that is systematically looking at protein quan….. What were they talking about? As …
Regulatory Expertise Now Part of QPS Clinical Development Offerings
In July 2015, regulatory expert Patricia Baede joined QPS’ clinical development teams. With 20 years of experience in clinical trial conduct and all regulatory aspects of drug development, Baede adds EU regulatory support to the growing portfolio of clinical activities QPS provides. In the past, she has worked on drug development teams as Phase I …
